Evopoint Biosciences Co., Ltd. (SHA:688837)
China · Delayed Price · Currency is CNY 49.40
+5.79 (13.28%)
Sep 30, 2026, 3:00 PM CST
Evopoint Biosciences Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Net Income | 408.51 | 202.56 | -386 | -426.89 | -462.63 |
Depreciation & Amortization | 40.39 | 40.39 | 25.88 | 17.62 | 14.91 |
Other Amortization | 4.16 | 4.16 | 4.92 | 5.7 | 4.79 |
Loss (Gain) From Sale of Assets | - | - | - | -0.05 | 0.1 |
Asset Writedown & Restructuring Costs | 0.04 | 0.04 | -0 | 0.14 | -0 |
Loss (Gain) From Sale of Investments | -156.8 | -156.8 | -64.62 | -19.87 | -48.83 |
Stock-Based Compensation | 140.73 | 140.73 | 17.09 | 34.05 | 58.75 |
Other Operating Activities | -84.33 | 29.61 | 15.73 | 7.07 | -5.51 |
Change in Accounts Receivable | -58.21 | -58.21 | -21.83 | -6.97 | 14.42 |
Change in Accounts Payable | -24.16 | -24.16 | 59.34 | 18.66 | 5.45 |
Operating Cash Flow | 270.32 | 178.3 | -349.49 | -370.55 | -418.55 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Capital Expenditures | -58.59 | -62.64 | -50.08 | -90.13 | -162.2 |
Sale of Property, Plant & Equipment | 0 | - | 0 | 0 | - |
Investment in Securities | -140.89 | 23.83 | 214.26 | 15.26 | 90.47 |
Other Investing Activities | 0.46 | 2.93 | 13.32 | 5.53 | 9.15 |
Investing Cash Flow | -199.02 | -35.88 | 177.51 | -69.34 | -62.58 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Long-Term Debt Issued | - | 767.31 | 176.2 | 128.98 | 329.92 |
Long-Term Debt Repaid | - | -409.39 | -59.01 | -63.9 | -2.6 |
Net Debt Issued (Repaid) | 457.01 | 357.92 | 117.19 | 65.08 | 327.32 |
Issuance of Common Stock | - | - | 150 | 512 | - |
Common Dividends Paid | -27.03 | -24.08 | -16.34 | -13.75 | -5.67 |
Other Financing Activities | -19.76 | -15.87 | -8.55 | -10.75 | -5.73 |
Financing Cash Flow | 410.22 | 317.96 | 242.3 | 552.58 | 315.92 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Foreign Exchange Rate Adjustments | -14.27 | -4.18 | -0.54 | 1.13 | 9.52 |
Net Cash Flow | 467.25 | 456.21 | 69.78 | 113.83 | -155.7 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | 211.72 | 115.66 | -399.57 | -460.68 | -580.75 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | 19.06% | 12.37% | - | - | -2978.22% |
Free Cash Flow Per Share | 0.57 | 0.31 | -1.09 | -1.35 | -1.78 |
Levered Free Cash Flow | - | 141.04 | -260.68 | -294.22 | - |
Unlevered Free Cash Flow | - | 155.96 | -250.75 | -289.35 | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash Income Tax Paid | 1.59 | -7.68 | 0.29 | -24.79 | -43.3 |
Change in Working Capital | -82.37 | -82.37 | 37.51 | 11.69 | 19.88 |